Illumina, Inc. (NASDAQ:ILMN) was upgraded by equities research analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a research report issued on Monday. The brokerage presently has a $195.00 price objective on the life sciences company’s stock. Leerink Swann’s price objective indicates a potential upside of 19.27% from the company’s current price.

A number of other equities analysts also recently weighed in on ILMN. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $141.42 target price on the stock. in a research note on Tuesday, December 13th. TheStreet downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Monday, December 5th. Cantor Fitzgerald restated a “neutral” rating and issued a $155.00 target price on shares of Illumina in a research note on Thursday, January 12th. Barclays PLC restated an “equal weight” rating and issued a $145.00 target price on shares of Illumina in a research note on Monday, January 9th. Finally, Robert W. Baird restated a “neutral” rating and issued a $153.00 target price (up previously from $147.00) on shares of Illumina in a research note on Thursday, January 12th. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $158.17.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Shares of Illumina (NASDAQ:ILMN) traded up 1.91% during midday trading on Monday, reaching $163.49. The company had a trading volume of 1,303,255 shares. The firm has a market capitalization of $23.92 billion, a P/E ratio of 53.25 and a beta of 0.79. The company has a 50 day moving average price of $163.67 and a 200-day moving average price of $152.69. Illumina has a one year low of $119.37 and a one year high of $186.88.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/illumina-inc-ilmn-upgraded-to-outperform-by-leerink-swann.html

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.03. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The firm had revenue of $619 million for the quarter, compared to the consensus estimate of $612.50 million. During the same quarter in the previous year, the business earned $0.81 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. On average, analysts anticipate that Illumina will post $3.64 EPS for the current fiscal year.

Your IP Address:

In other news, EVP Omead Ostadan sold 259 shares of the company’s stock in a transaction on Monday, January 30th. The shares were sold at an average price of $160.90, for a total value of $41,673.10. Following the transaction, the executive vice president now owns 27,949 shares of the company’s stock, valued at $4,496,994.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction on Friday, February 17th. The stock was sold at an average price of $162.80, for a total transaction of $97,680.00. Following the completion of the transaction, the director now directly owns 17,065 shares in the company, valued at approximately $2,778,182. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,698 shares of company stock worth $2,043,274. Insiders own 1.60% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Global X Management Co. LLC boosted its position in Illumina by 1,400.0% in the third quarter. Global X Management Co. LLC now owns 600 shares of the life sciences company’s stock valued at $109,000 after buying an additional 560 shares during the last quarter. Penserra Capital Management LLC boosted its position in Illumina by 94.5% in the third quarter. Penserra Capital Management LLC now owns 708 shares of the life sciences company’s stock valued at $128,000 after buying an additional 344 shares during the last quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund purchased a new position in Illumina during the third quarter valued at $171,000. Stanford Investment Group Inc. boosted its position in Illumina by 5.7% in the fourth quarter. Stanford Investment Group Inc. now owns 1,400 shares of the life sciences company’s stock valued at $179,000 after buying an additional 75 shares during the last quarter. Finally, Patten & Patten Inc. TN bought a new position in shares of Illumina during the third quarter valued at about $211,000. 92.79% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

5 Day Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.